HCPLive Podcasts - Podcasts
Podcast

HCPLive Podcasts

HCPLive.com
0 Plays

Listen to your favorite podcasts on RadaRadio. Thousands of podcasts at your fingertips.

Latest Episodes

Allergy Rounds With Dr. Autumn I Introduction

10 Nov 2026
2:42

Allergy Rounds With Dr. Autumn Host: Autumn Burnette, MD, from Howard University Watch here: https://www.hcplive.com/view/allergy-rounds-dr-autumn-introduction

Joint Ventures ACR 2026 Preview: 6 Abstracts Rheumatologists Should Watch

03 Nov 2026
42:31

A recent episode of the Joint Ventures podcast previewed six abstracts for ACR Convergence 2026, held November 6 to 11 in Orlando, Florida. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, each selected three from nearly 3,000 abstracts. Their picks span checkpoint inhibitor arthritis, psoriatic arthritis biomarkers, novel imaging, JAK inhibitor prescribing, and tis…

Joint Ventures: Gout Management Gaps Persist Despite Effective Therapies, Guidelines

29 Oct 2026
26:58

Gout remains poorly managed at the population level despite a well-understood pathophysiology, established serum urate targets, and an expanding pharmacological toolkit, according to a recent episode of the rheumatology podcast Joint Ventures. Hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, consultant rheumatologist at Freeman Hospital, Newcastle, reviewed current guidelines, emerging trial data, and the pipeline in gout …

Joint Ventures Recaps Influential EULAR Studies in SLE, RA, and More

16 Jul 2026
42:02

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD (academic clinical lecturer in rheumatology, University of Leeds), and Rihards Buss, MD (consultant rheumatologist, Freeman Hospital, Newcastle), record a post-EULAR 2026 debrief, working through the abstracts each identified as the meeting's most consequential. The conversation spans cellular therapies in autoimmune disease, proteomic biomarkers for treatment selection in RA, a landmark head-to-head trial in psoriatic arthritis, ev…

Liver Lineup: Bepirovirsen and the Push Toward Functional Cure in Hepatitis B

09 Jul 2026
42:58

Could hepatitis B finally have a finite treatment option? Tatyana Kushner, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to break down the phase 3 B-Well data for bepirovirsen, the first agent to hit functional cure as a primary endpoint in chronic hepatitis B. The conversation covers the phase 3 B-Well 1 and B-Well 2 results, published in the New England Journal of Medicine and presented at EASL 2026, and why quantitative HBsAg testing is becoming essential to patient selection ahead …

Liver Lineup: HDV Diagnosis, Bulevirtide, and the Delta Pipeline

09 Jul 2026
44:44

In this episode of Liver Lineup: Updates and Unfiltered Insights, hosts Kimberly Brown, MD (Henry Ford Hospital), and Nancy Reau, MD (Rush University Medical Center), are joined by Tatyana Kushner, MD (Weill Cornell Medicine), to discuss hepatitis delta virus (HDV). Topics covered: Why fewer than 10% of HBsAg-positive patients have ever been tested for HDV — and why that needs to change The diagnostic cascade from HDV antibody to HDV RNA, and barriers to reflex testing implementation The recent …

Joint Ventures: Lupus Health Inequalities, Growing Burden of ICI-Arthritis at EULAR 2026

26 Jun 2026
13:26

In this episode of Joint Ventures, host Rihards Buss, MD, consultant rheumatologist, Freeman Hospital, Newcastle, sits down with Sarah Dyball, MBBS, PhD, academic clinical lecturer, Centre for Musculoskeletal Research, University of Manchester, and Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London. Click here to watch the episode.

Joint Ventures: CAR-T, Early Diagnosis Reshape Scleroderma at EULAR 2026

24 Jun 2026
13:18

The therapeutic framework for systemic sclerosis is undergoing a fundamental reorientation, moving away from managing visible fibrotic sequelae toward targeting the autoantibody-driven mechanisms believed to initiate and propagate disease. On a recent episode of Joint Ventures recorded live at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London, host Jack Arnold, MBBS, PhD, of the University of Leeds, spoke with Vishal Kakkar, MD, also of the University of Leed…

Joint Ventures: Aiming for Targeted First-Line Therapy in Early RA at EULAR 2026

24 Jun 2026
7:30

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, academic clinical lecturer in rheumatology, University of Leeds, was joined at the European Alliance of Associations for Rheumatology (EULAR) 2026 annual congress in London by Laurence Duquenne, MD, a rheumatology researcher, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, an investigator on one of the meeting's standout studies to examine whether baseline naïve CD4+ T cell frequency can identify whi…

Joint Ventures: EULAR 2026 Congress Preview

29 May 2026
42:37

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including: Obesity, Weight Management, and Psoriatic Arthrit…

Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus

28 May 2026
36:07

In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed. The episode examines the biologic rationale behind combining rituximab wi…

Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier

28 May 2026
29:38

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has prove…

Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

28 May 2026
27:54

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1…

Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1

28 May 2026
28:45

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, examine the growing evidence for GLP-1 receptor agonists in rheumatological disease — drugs originally developed for glycemic control that are now drawing serious attention as potential immunomodulators with implications across the specialty. The conversation opens by tracing th…

Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms

28 May 2026
25:00

In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared go…

Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS

28 May 2026
22:39

Introducing Joint Ventures — a new podcast exploring advances in rheumatologic disease and what they mean for real-world practice. Hosted by RheumatologyLive, the series is led by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 United Kingdom-based rheumatologists united by a shared interest in translating rapidly evolving science into thoughtful, patient-centered care. Joint Ventures is designed for rheumatologists and clinicians managing immune-mediated disease who are navigating an increasi…

Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

06 May 2026
11:00

Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class. Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therap…

FSGS Drug Development No Longer a ‘Graveyard’: What Comes After Sparsentan’s Approval

19 Apr 2026
13:47

Liver Lineup: Closing the Gap in Women’s Liver Health

16 Apr 2026
44:51

In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Meena Bansal, MD, to examine how liver disease uniquely affects women across the lifespan. While conditions like metabolic dysfunction-associated steatotic liver disease (MASLD) are often discussed in broad terms, the trio highlights how risk, progression, and outcomes can differ significantly based on sex and hormonal status. From reproductive years through menopause and beyond, physiologic changes play…

Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease

07 Apr 2026
56:11

In this episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Saul Karpen, MD, PhD, and Robert Gish, MD, for a practical, clinician-focused discussion on the evolving role of genetic testing in cholestatic liver disease. As genetic panels become more widely used in hepatology, many clinicians are left wondering when to order these tests—and how to interpret the results when they come back. From unexplained cholestasis and AMA-negative PBC to intrahepatic cholestasi…

Podcasts

Comments & Reviews0